Literature DB >> 17703930

Biochemistry and therapeutic implications of mechanisms involved in FOXP3 activity in immune suppression.

Bin Li1, Sandra J Saouaf, Arabinda Samanta, Yuan Shen, Wayne W Hancock, Mark I Greene.   

Abstract

While mutations in human FOXP3 predispose individuals to autoimmune conditions, it is unclear how the mutant protein fails to function as a transcriptional regulator. There is also limited detail of how FOXP3 itself interacts with the transcriptional machinery and which components of the FOXP3 ensembles exert phenotypic changes to render cells able to mediate suppression. Increasing evidence indicates that the level and duration of FOXP3 expression plays a crucial role in the development and function of natural regulatory T cells (Tregs). Our studies focus on the post-translational modification of the FOXP3 protein, and how the FOXP3 complex ensemble, containing histone modification and chromatin-remodeling enzymes, defines its functional role in regulatory T cells. Understanding the molecular mechanisms underlying FOXP3 activity will provide therapeutic implications for transplantation, allergy, autoimmune disease and cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17703930     DOI: 10.1016/j.coi.2007.07.006

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  18 in total

Review 1.  The biology of FoxP3: a key player in immune suppression during infections, autoimmune diseases and cancer.

Authors:  Frances Mercer; Derya Unutmaz
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

2.  Multipotent mesenchymal stromal cells express FoxP3: a marker for the immunosuppressive capacity?

Authors:  Mikael Sundin; Pádraig D'arcy; C Christian Johansson; A John Barrett; Helena Lönnies; Berit Sundberg; Silvia Nava; Rolf Kiessling; Dimitrios Mougiakakos; Katarina Le Blanc
Journal:  J Immunother       Date:  2011-05       Impact factor: 4.456

3.  Low molecular weight fraction secreted by SKOV3 cells expands peripheral CD4+CD25+ regulatory T cells and enhances their suppressive capacity.

Authors:  Xiao Li; Xiaoyun Wan; Yuyan Mao; Weiguo Lu; Xing Xie
Journal:  Med Oncol       Date:  2009-06-17       Impact factor: 3.064

4.  Structural and biological features of FOXP3 dimerization relevant to regulatory T cell function.

Authors:  Xiaomin Song; Bin Li; Yan Xiao; Chunxia Chen; Qiang Wang; Yujie Liu; Alan Berezov; Chen Xu; Yayi Gao; Zhiyuan Li; Shiaw-Lin Wu; Zheng Cai; Hongtao Zhang; Barry L Karger; Wayne W Hancock; Andrew D Wells; Zhaocai Zhou; Mark I Greene
Journal:  Cell Rep       Date:  2012-06-15       Impact factor: 9.423

Review 5.  Immune regulation by histone deacetylases: a focus on the alteration of FOXP3 activity.

Authors:  Hongtao Zhang; Yan Xiao; Zhiqiang Zhu; Bin Li; Mark I Greene
Journal:  Immunol Cell Biol       Date:  2011-11-29       Impact factor: 5.126

6.  BRG1-mediated immune tolerance: facilitation of Treg activation and partial independence of chromatin remodelling.

Authors:  Barbara H Chaiyachati; Anant Jani; Yisong Wan; Haichang Huang; Richard Flavell; Tian Chi
Journal:  EMBO J       Date:  2013-01-15       Impact factor: 11.598

Review 7.  FOXP3 and its partners: structural and biochemical insights into the regulation of FOXP3 activity.

Authors:  Zhaocai Zhou; Xiaomin Song; Bin Li; Mark I Greene
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

8.  CD28 costimulation is essential for human T regulatory expansion and function.

Authors:  Tatiana N Golovina; Tatiana Mikheeva; Megan M Suhoski; Nicole A Aqui; Victoria C Tai; Xiaochuan Shan; Ronghua Liu; R Robert Balcarcel; Nancy Fisher; Bruce L Levine; Richard G Carroll; Noel Warner; Bruce R Blazar; Carl H June; James L Riley
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

Review 9.  Regulatory T cells and treatment of cancer.

Authors:  Tyler J Curiel
Journal:  Curr Opin Immunol       Date:  2008-05-27       Impact factor: 7.486

Review 10.  T-cell tolerance in cancer.

Authors:  Junmei Wang; Anupama Sahoo; Roza Nurieva
Journal:  Immunotherapy       Date:  2013-05       Impact factor: 4.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.